AbbVie Inc (ABBV)vsZEN Graphene Solutions Ltd (ZTEK)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ZTEK
ZEN Graphene Solutions Ltd
$0.43
+0.78%
HEALTHCARE · Cap: $48.29M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6486410% more annual revenue ($61.16B vs $942,880). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ZTEK
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+89.6%
Fair Value
$6.28
Current Price
$0.43
$5.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 73.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -56.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while ZTEK is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ZTEK is growing revenue faster at 73.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 23/100). ZTEK offers better value entry with a 89.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is at the forefront of materials technology, specializing in the development and commercialization of high-purity graphene products derived from natural graphite. By leveraging proprietary extraction techniques, ZTEK aims to transform diverse sectors, including environmental remediation, energy storage, and advanced manufacturing, with its graphene-based solutions. The company's strong emphasis on sustainability, paired with ongoing research and development initiatives, positions it as a leader in the graphene technology market. As ZTEK exploits growth opportunities and drives innovation, it is poised to enhance long-term shareholder value amid a growing global demand for advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?